TY - JOUR
T1 - Molecular characterization and clinical impact of human bocavirus at a tertiary hospital in Barcelona (Catalonia, Spain) during the 2014–2017 seasons
AU - Piñana, Maria
AU - Vila, Jorgina
AU - Andrés, Cristina
AU - Saura, Jordi
AU - González-Sánchez, Alejandra
AU - Creus-Costa, Anna
AU - Saubi, Narcís
AU - Esperalba, Juliana
AU - Rando, Ariadna
AU - Iglesias-Cabezas, Manuel Jesús
AU - Quer, Josep
AU - Soriano-Arandes, Antoni
AU - Soler-Palacín, Pere
AU - Pumarola, Tomàs
AU - Antón, Andrés
N1 - Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
PY - 2022/11/19
Y1 - 2022/11/19
N2 - Purpose: The aim was to describe the prevalence, molecular epidemiology and clinical manifestations of human bocavirus (HBoV) in patients attended at a tertiary hospital in Barcelona, Spain. Methods: From October 2014 to May 2017, respiratory specimens from paediatric patients were collected for respiratory viruses’ laboratory-confirmation. Phylogenetic analyses from partial VP1 sequences were performed from all HBoV laboratory-confirmed specimens. Clinical features were retrospectively studied. Results: 178/10271 cases were HBoV laboratory-confirmed. The median age was 1.53 (IQR 1.0–2.3). Co-detection was highly reported (136; 76%). All viruses belonged into HBoV1 genotype but one into HBoV2. Non-reported mutations were observed and two sites were suggestive to be under negative selection. 61% (109/178) cases had lower RTI (LRTI), of whom 84 had co-detections (77%) and 76 had comorbidities (70%). LRTI was the cause of hospitalization in 85 out of 109 cases (78%), and no differences were found regarding severity factors during hospitalization between co- and single-detections, except for median length of respiratory support, which was longer in cases with co-detections. Conclusions: Close monitoring of predominant HBoV1 showed a high similarity between viruses. The presence of comorbidities might explain the high prevalence of LRTI. Symptomatology in HBoV single-detected cases suggest that HBoV is a true pathogen.
AB - Purpose: The aim was to describe the prevalence, molecular epidemiology and clinical manifestations of human bocavirus (HBoV) in patients attended at a tertiary hospital in Barcelona, Spain. Methods: From October 2014 to May 2017, respiratory specimens from paediatric patients were collected for respiratory viruses’ laboratory-confirmation. Phylogenetic analyses from partial VP1 sequences were performed from all HBoV laboratory-confirmed specimens. Clinical features were retrospectively studied. Results: 178/10271 cases were HBoV laboratory-confirmed. The median age was 1.53 (IQR 1.0–2.3). Co-detection was highly reported (136; 76%). All viruses belonged into HBoV1 genotype but one into HBoV2. Non-reported mutations were observed and two sites were suggestive to be under negative selection. 61% (109/178) cases had lower RTI (LRTI), of whom 84 had co-detections (77%) and 76 had comorbidities (70%). LRTI was the cause of hospitalization in 85 out of 109 cases (78%), and no differences were found regarding severity factors during hospitalization between co- and single-detections, except for median length of respiratory support, which was longer in cases with co-detections. Conclusions: Close monitoring of predominant HBoV1 showed a high similarity between viruses. The presence of comorbidities might explain the high prevalence of LRTI. Symptomatology in HBoV single-detected cases suggest that HBoV is a true pathogen.
KW - Clinical impact
KW - Human bocavirus
KW - Molecular characterization
KW - Surveillance
KW - Tertiary Care Centers
KW - Humans
KW - Infant
KW - Parvoviridae Infections/epidemiology
KW - Viruses
KW - Phylogeny
KW - Respiratory Tract Infections/diagnosis
KW - Retrospective Studies
KW - Seasons
KW - Spain/epidemiology
KW - Child
KW - Human bocavirus/genetics
UR - http://www.scopus.com/inward/record.url?scp=85142134160&partnerID=8YFLogxK
U2 - 10.1007/s15010-022-01955-z
DO - 10.1007/s15010-022-01955-z
M3 - Article
C2 - 36401674
AN - SCOPUS:85142134160
SN - 0300-8126
VL - 51
SP - 935
EP - 943
JO - Infection
JF - Infection
IS - 4
ER -